12
Jun
2014

Your IPF Patients Have Access to Pirfenidone at Creighton

The 2013 American Thoracic Society Guidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis (available at www.nxtbook.com/nxtbooks/md_conference_express/ATSIPF/index.php?startid=24#/0) essentially recommends that we SHOULD NOT TREAT patients with IPF given the lack of efficacy of most treatments coupled with the potential toxicity of available agents. However, since that publication was drafted three major new studies have been published in the New England Journal of Medicine that may require us to revisit this conclusion.

The first study appears to be the final nail in the coffin for N-acetyl cysteine in IPF as patients given NAC fared no better than their placebo-treated comparators (The Idiopathic Pulmonary Fibrosis Clinical Research Network. N Engl J Med 2014; 370:2093-2101). The second study (Richeldi L., du Bois R.M., Raghu G., et al. N Engl J Med 2014; 370:2071-2082) showed that the tyrosine kinase inhibitor nintedanib led to a reduced rate of decline in the forced vital capacity (FVC) over time. While promising, this molecule is relatively early-on in the prolonged FDA-approval process. The third study (King T.E., Bradford W.Z., Castro-Bernardini S., et al.N Engl J Med 2014; 370:2083-2092) found that pirfenidone – already approved for use in IPF in most of the rest of the world – significantly reduces the rate of decline in FVC and DLCO.

Given the paucity of effective therapies for IPF here in the U.S. and the consequences of untreated disease, it is anticipated that the FDA will approve pirfenidone making it the first/only agent indicated for this disease state. However, the FDA’s action is not anticipated to happen quickly for a variety of reasons. In an effort to get this apparently effective therapy into the hands of anxious IPF patients as quickly as possible, the manufacturer of pirfenidone (Intermune) has allowed sites who participated in prior pirfenidone trials to apply to become Early Access Providers. Given the involvement of Creighton Pulmonary with this agent for the past several years, we are one of a handful of centers authorized to provide patients with pirfenidone. For those patients meeting appropriate criteria, we can provide them with pirfenidone free of charge in return for their agreement to allow us to do safety monitoring (blood work). We have been swamped with patients coming to Omaha from Wyoming, Minnesota, Wiconsin, Missouri, Oklahoma, Kansas, etc. in the hopes they can be started on therapy.

If you have interested IPF patients – send them our way. If not – keep your eyes open for more regarding the evolution of therapy in this area.

5 Responses

  1. mgbadamosi

    Thank you Dr Morrow for your post.
    In review
    1)Pirfenidone is an oral antifibrotic agent studied in the treatment of IPF
    2)A recent study in NEJM showed that it significantly slows the decline in FVC/DLCO in IPF patients
    http://blogs.creighton.edu/im/files/2014/06/Pirfenidone.pdf
    3)It is not FDA approved, but its approval is anticipated
    4) It is available at Creighton due to our involvement in IPF research.

  2. Hamza Tantoush

    Thank you Dr. Morrow for your interesting post. You did mention patients should have certain criteria to be qualified for the treatment .
    I wonder if you kindly explain to us what are the criteria ?
    Does patients with IPF need workup prior to send him to pulmonary clinic ?

  3. Lee Morrow

    Great point by Dr. Tantoush. Although my post was intended more to educate regarding IPF and highlight research activities at our hospital than to recruit patients, the inclusion and exclusion criteria should be mentioned…

    For patients to get pirfenidone through the EAP they must have: (1) a CT or lung biopsy confirming a usual interstitial pneumonia (UIP) pattern; (2) FVC >50% predicted; and (3) DLCO >30% predicted. That’s it. Very liberal inclusion criteria.

    The only exclusion criteria are: (1) currently on another investigational product; (2) on fluvoxamine therapy; (3) current smokers who are unwilling to quit; and (4) pregnancy or lactation.

So, what do you think?

Follow

Get a quick update with every new post -- no spam ever!

Facebook Auto Publish Powered By : XYZScripts.com